scholarly journals Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0177231 ◽  
Author(s):  
Fiona Maas ◽  
Suzanne Arends ◽  
Freke R. Wink ◽  
Reinhard Bos ◽  
Hendrika Bootsma ◽  
...  
Keyword(s):  
At Risk ◽  
Ankylosing Spondylitis ◽  
Radiographic Progression ◽  
Term Treatment ◽  
Radiographic Outcome ◽  
Tnf Α ◽  
Long Term Treatment ◽  
Patients At Risk

scholarly journals Sustained Low Disease Activity Measured By ASDAS Slow Radiographic Spinal Progression in Axial Spondyloarthritis Patients Treated With TNF-inhibitors. Data from REGISPONSERBIO

2021 ◽  
Author(s):  
Maria Llop ◽  
Mireia Moreno ◽  
Victoria Navarro-Compán ◽  
Xavier Juanola ◽  
Eugenio de Miguel ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Radiographic Progression ◽  
Axial Spondyloarthritis ◽  
Term Treatment ◽  
Tnf Inhibitors ◽  
Low Disease Activity ◽  
Long Term Treatment

Abstract Background: To evaluate the influence of the disease activity on radiographic progression in axial spondyloarthritis (axSpA) patients treated with TNF inhibitors (TNFi).Methods: The study included 101 axSpA patients from the Spanish Register of Biological Therapy in Spondyloarthritides (REGISPONSERBIO), which had clinical data and radiographic assessment available. Patients were classified into 2 groups based on the duration of TNFi treatment at baseline: i) long-term treatment (≥4 years) and ii) no long-term treatment (< 4 years). Radiographs were scored by two readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) with known chronology. Disease activity differences between patients’ groups at each time point were assessed using a linear mixed-effect model.Results: Radiographic progression was defined as an increase in ≥2 mSASSS units. At inclusion, approximately half of the patients (45.5%) were receiving long-term treatment with TNFi (≥4 years). In this group of subjects, a significant difference in averaged Ankylosing Spondylitis disease Activity Score (ASDAS) across follow-up was found between progressors and non-progressors (2.33 vs 1.76, p=0.027, respectively). In patients not under long-term TNFi treatment (54.5%) though, no significant ASDAS differences were observed between progressors and non-progressors until the third year of follow-up. Furthermore, no significant differences were found in progression status, when disease activity was measured by Bath Ankylosing spondylitis Disease Activity Index (BASDAI) and C reactive protein (CRP).Conclusions: Patients on long-term TNFi treatment with a mean sustained low disease activity measures by ASDAS presented lower radiographic progression than those with active disease.

scholarly journals TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment

Rheumatology ◽  
2014 ◽  
Vol 53 (7) ◽  
pp. 1250-1255 ◽  
Author(s):  
Mihaela C. Micu ◽  
Romeo Micu ◽  
Stela Surd ◽  
Marinela Gîrlovanu ◽  
Sorana D. Bolboacă ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Sperm Quality ◽  
Term Treatment ◽  
Short Term ◽  
Tnf Α ◽  
Long Term Treatment

TNF-Inhibitoren verlangsamen die radiologische Progression bei Patienten mit ankylosierender Spondylitis

2020 ◽  
pp. 1-3
Author(s):  
Carmen-Marina Mihai
Keyword(s):  
Ankylosing Spondylitis ◽  
Structural Model ◽  
Radiographic Progression ◽  
Term Treatment ◽  
Marginal Structural Model ◽  
Real World Data ◽  
Change Rate ◽  
Long Term Treatment ◽  
The Difference

<b>Objectives:</b> Tumour necrosis factor inhibitors (TNFis) have been suggested to slow radiographic progression in patients with ankylosing spondylitis. However, limitations such as variations in disease activity, complex drug administration and short follow-up duration make it difficult to determine the effect of TNFis on radiographic progression. The aim of the study was to investigate whether long-term treatment with TNFis can reduce radiographic progression in patients with ankylosing spondylitis using 18-year longitudinal real-world data. <b>Methods:</b> This retrospective study was conducted between January 2001 and December 2018 at a single centre. Among the 1280 patients whose electronic medical records were reviewed, data of 595 patients exposed to TNFis at least once were included. Among them, time intervals of TNFi exposure or non-exposure were determined in 338 patients (‹on the TNFis› or ‹off the TNFis› intervals, respectively). The difference in the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) change rate between ‹on the TNFis› and ‹off the TNFis› intervals was investigated. <b>Results:</b> We obtained 2364 intervals of 338 patients (1281 ‹on the TNFis› and 1083 ‹off the TNFis› intervals). In the marginal structural model for inverse probability of treatment weighting, the change rate of mSASSS significantly decreased with the use of TNFis (β = –0.112, p = 0.004), and the adjusted mSASSS changes were 0.848 and 0.960 per year during ‹on the TNFis› and ‹off the TNFis› intervals, respectively. <b>Conclusion:</b> Compared with treatment without TNFis, treatment with TNFis slowed radiologic progression significantly.

scholarly journals Long-Term Treatment of Cuban Policosanol Attenuates Abnormal Oxidative Stress and Inflammatory Response via Amyloid Plaques Reduction in 5xFAD Mice

Antioxidants ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1321
Author(s):  
Jin-Ho Kim ◽  
Dong-Kyun Lim ◽  
Yoo-Hun Suh ◽  
Keun-A Chang
Keyword(s):  
Neurodegenerative Disorder ◽  
Lipid Peroxide ◽  
Amyloid Plaques ◽  
Term Treatment ◽  
Number Of Patients ◽  
Tnf Α ◽  
Long Term Treatment ◽  
5Xfad Mice ◽  
The Brain

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder resulting in cognitive decline or dementia, the number of patients with AD is continuously increasing. Although a lot of great progress has been made in research and development of AD therapeutics, there is no fundamental cure for this disease yet. This study demonstrated the memory-improving effects of Cuban policosanol (PCO) in 5xFAD mice, which is an animal model of AD. Following 4-months of treatment with PCO in 5xFAD mice, we found that the number of amyloid plaques decreased in the brain compared to the vehicle-treated 5xFAD mice. Long-term PCO treatment in 5xFAD mice resulted in the reduction of gliosis and abnormal inflammatory cytokines level (interleukin [IL]-1β, IL-6, and tumor necrosis factor [TNF]-α) in the cortex and hippocampus. Levels of lipid peroxide (4-hydroxynonenal [4-HNE]) and superoxide dismutase (SOD1 and SOD2) levels were also recoverd in the brains of PCO-treated 5xFAD mice. Notably, PCO administration reduced memory deficits in the passive avoidance test, as well as synaptic loss (PSD-95, synaptophysin) in 5xFAD mice. Collectively, we identified the potential effects of PCO as a useful supplement to delay or prevent AD progression by inhibiting the formation of Aβ plaques in the brain.

Sign in / Sign up

Export Citation Format

Share Document